Bioregulator
    Research Only

    Vilon

    Also known as: Vilon bioregulator, Lys-Glu dipeptide, KE peptide

    Vilon is a synthetic dipeptide consisting of lysine and glutamic acid (Lys-Glu), developed by Professor Vladimir Khavinson as a bioregulator peptide targeting the thymus gland. The thymus is the primary organ responsible for T-cell maturation and plays a critical role in adaptive immune function. With aging, the thymus undergoes involution, leading to progressive immunosenescence characterised by declining T-cell diversity and impaired immune surveillance. Vilon is proposed to modulate thymic gene expression, potentially restoring aspects of thymic function and supporting T-cell differentiation. As a dipeptide bioregulator, it represents the smallest functional unit in the Khavinson bioregulation framework, theorised to interact with DNA to normalise immune gene expression.

    View Product

    Research overview

    Vilon, also known as the Lys-Glu dipeptide or KE peptide, is a bioregulator compound extensively studied for its potential effects on immune system function in research models. This dipeptide is theorised to penetrate cell membranes and interact with DNA sequences in thymic epithelial cells, modulating the expression of genes involved in T-cell development and thymic microenvironment maintenance. In laboratory studies, Vilon demonstrates the ability to influence chromatin condensation and transcriptional activity, potentially restoring age-related decline in thymopoiesis. Research indicates that this bioregulator may promote differentiation of T-cell precursors, enhance thymic epithelial cell function, and support maintenance of T-cell receptor diversity in experimental models. Primary research effects observed include modulation of T-cell differentiation, support of thymic function, and potential enhancement of immune surveillance mechanisms. Studies suggest Vilon may contribute to restoration of thymic gene expression and mitigation of immunosenescence processes in research settings. The evidence base for Vilon is derived primarily from preclinical studies and observational reports. In vitro studies have demonstrated that the Lys-Glu dipeptide can influence gene expression in immune cell cultures, whilst animal studies have shown evidence of immune modulation. However, researchers should note that no controlled human clinical trials meeting international standards have been published, placing the evidence grade at level D. Vilon represents an important research tool for investigating bioregulatory mechanisms in immune system function and thymic biology.

    Mechanism of action

    Vilon (Lys-Glu) is theorised to penetrate cell membranes and interact with DNA sequences in thymic epithelial cells, modulating expression of genes involved in T-cell development and thymic microenvironment maintenance. This interaction may influence chromatin condensation and transcriptional activity, potentially restoring age-related decline in thymopoiesis. The peptide may promote differentiation of T-cell precursors, enhance thymic epithelial cell function, and support maintenance of T-cell receptor diversity.

    Frequently asked questions